Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2000

View Archived Issues

Encouraging preclinical data reported for BioSante's CAP vaccine adjuvant

Bentley obtains license from Dartmouth for novel use of androgen therapy

Galenica and U.S. Navy to evaluate malaria vaccine adjuvant

Xenova: summary of product pipeline progress in first three quarters of 2000

PPL Therapeutics expands focus to include treatment of diabetes

Lilly's Zyprexa approved by FDA for extended schizophrenia indication

Cellegy seeks approval of Rectogesic in New Zealand

SmithKline Beecham launches Argatroban in U.S.

Interleukin Genetics and Brigham & Women's Hospital investigate genetic control of inflammation

ZK-229561/NVP-ABP-008: a selective KDR kinase inhibitor for the treatment of solid tumors

Irreversible EGF receptor kinase inhibitor EKB-569 advanced to phase I trials in cancer patients

FK-3311 reduces ischemia/reperfusion injury to the lung in rat model

Vascular targeting agent for cancer therapy profiled at NCI-EORTC-AACR symposium

Ono-5046 ameliorates lower limb ischemia/reperfusion injury

Ranolazine, a first-in-class antianginal agent, a highlight at AHA scientific sessions

Independent safety board recommends continuation of Theratope vaccine phase III trial

S-9156 shows efficacy as oxygen carrier in preclinical studies

Cardioprotective effect of AMP-579 appears to involve activation of a survival signal pathway

Tanox MAb suppresses complement, neutrophil, platelet and cytokine activation during CPB

New pure antiestrogen with promising activity in breast cancer discovered at Schering

Novel voltage-sensitive sodium channel blockers designed by CoCensys

Antiarrhythmic agents with a chroman structure patented by Nissan Chemical

Two series of styryl sulfone antitumor agents reported recently by U.S. university researchers

Inhibitors of LFA-1 binding to ICAMs in development at Icos

Ono describes new MMP inhibitors and their potential therapeutic applications

Pfizer prepares series of 2-pyridinylguanidine urokinase inhibitors

AHA news: studies on a selective PAR-1 antagonist indicate potential in restenosis

Novel series for eating and metabolic disorders identified at ADIR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...